BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36995935)

  • 21. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
    Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
    Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissecting the role of H3K27 acetylation and methylation in PRC2 mediated control of cellular identity.
    Lavarone E; Barbieri CM; Pasini D
    Nat Commun; 2019 Apr; 10(1):1679. PubMed ID: 30976011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of Polycomb Repressive Complex 2 to RNA by Short Repeats of Consecutive Guanines.
    Wang X; Goodrich KJ; Gooding AR; Naeem H; Archer S; Paucek RD; Youmans DT; Cech TR; Davidovich C
    Mol Cell; 2017 Mar; 65(6):1056-1067.e5. PubMed ID: 28306504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8
    Gray SM; Amezquita RA; Guan T; Kleinstein SH; Kaech SM
    Immunity; 2017 Apr; 46(4):596-608. PubMed ID: 28410989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRC2 activates interferon-stimulated genes indirectly by repressing miRNAs in glioblastoma.
    Shivram H; Le SV; Iyer VR
    PLoS One; 2019; 14(9):e0222435. PubMed ID: 31513636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Elongation Factor Spt6 Maintains ESC Pluripotency by Controlling Super-Enhancers and Counteracting Polycomb Proteins.
    Wang AH; Juan AH; Ko KD; Tsai PF; Zare H; Dell'Orso S; Sartorelli V
    Mol Cell; 2017 Oct; 68(2):398-413.e6. PubMed ID: 29033324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.
    Lau-Corona D; Bae WK; Hennighausen L; Waxman DJ
    PLoS Genet; 2020 May; 16(5):e1008796. PubMed ID: 32428001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent High Glucose Elevates Nuclear Localization of EZH2 to Cause H3K27me3-Dependent Repression of KLF2 Leading to Endothelial Inflammation.
    Thakar S; Katakia YT; Ramakrishnan SK; Pandya Thakkar N; Majumder S
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH1 in germ cells safeguards the function of PRC2 during spermatogenesis.
    Mu W; Starmer J; Shibata Y; Yee D; Magnuson T
    Dev Biol; 2017 Apr; 424(2):198-207. PubMed ID: 28254491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new kinetochore component CENP-W interacts with the polycomb-group protein EZH2 to promote gene silencing.
    Koh W; Park B; Lee S
    Biochem Biophys Res Commun; 2015 Aug; 464(1):256-62. PubMed ID: 26111449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
    Anwar T; Gonzalez ME; Kleer CG
    Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
    Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
    Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.
    Gherardi S; Ripoche D; Mikaelian I; Chanal M; Teinturier R; Goehrig D; Cordier-Bussat M; Zhang CX; Hennino A; Bertolino P
    Biochim Biophys Acta Gene Regul Mech; 2017 Apr; 1860(4):427-437. PubMed ID: 28215965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.
    Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
    Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.
    Brien GL; Bressan RB; Monger C; Gannon D; Lagan E; Doherty AM; Healy E; Neikes H; Fitzpatrick DJ; Deevy O; Grant V; Marqués-Torrejón MA; Alfazema N; Pollard SM; Bracken AP
    Nat Genet; 2021 Aug; 53(8):1221-1232. PubMed ID: 34294917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
    Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
    Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.